201. Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrier.
- Author
-
Perrone MG, Vitale P, Ferorelli S, Boccarelli A, Coluccia M, Pannunzio A, Campanella F, Di Mauro G, Bonaccorso C, Fortuna CG, and Scilimati A
- Subjects
- Animals, Blood-Brain Barrier drug effects, Cell Line, Central Nervous System metabolism, Cyclooxygenase Inhibitors chemical synthesis, Cyclooxygenase Inhibitors chemistry, Dose-Response Relationship, Drug, Galactose chemistry, Glucose Transporter Type 1 metabolism, Humans, Isoxazoles chemistry, Mice, Models, Molecular, Molecular Structure, Structure-Activity Relationship, Central Nervous System drug effects, Cyclooxygenase 1 metabolism, Cyclooxygenase Inhibitors pharmacology, Galactose pharmacology, Glucose Transporter Type 1 antagonists & inhibitors, Isoxazoles pharmacology
- Abstract
Neuroinflammation is the earliest stage of several neurological and neurodegenerative diseases. In the case of neurodegenerative disorders, it takes place about 15-20 years before the appearance of specific neurodegenerative clinical symptoms. Constitutive microglial COX-1 is one of the pro-inflammatory players of the neuroinflammation. Novel compounds 3, 14 and 15 (Galmof
0 , Galmof5 and Galmof11 , respectively) were projected, and their synthetic methodologies developed, by linking by an ester bond, directly or through a C5 or C11 unit linker the highly selective COX-1 inhibitor mofezolac (COXs selectivity index > 6000) to galactose in order to obtain substances capable to cross blood-brain barrier (BBB) and control the CNS inflammatory response. 3, 14 and 15 (Galmofs) were prepared in good to fair yields. Galmof0 (3) was found to be a selective COX-1 inhibitor (COX-1 IC50 = 0.27 μM and COX-2 IC50 = 3.1 μM, selectivity index = 11.5), chemically and metabolically stable, and capable to cross Caco-2 cell monolayer, resembling BBB, probing that its transport is GLUT-1-mediated. Furthermore, Galmof0 (3) powerfully inhibits PGE2 release higher than mofezolac (1) in LPS-stimulated mouse BV2 microglial cell line, a worldwide recognized neuroinflammation model. In addition, Fingerprints for Ligands and Proteins (FLAP) was used to explain the different binding interactions of Galmofs with the COX-1 active site., (Copyright © 2017 Elsevier Masson SAS. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF